Recent Updates
Recently added Catalysts
NKTX Positive Sentiment Score: 70/100

Nkarta to Participate at Upcoming Investor Conferences

Thursday, February 9, 2023 1 min read
Key Takeaway: Nkarta, Inc. (Nasdaq: NKTX) has announced its participation in three upcoming investor conferences, highlighting its commitment to engaging with the investment community. The conferences include the SVB Securities Global Biopharma Conference, the H.C. Wainwright Cell Therapy Virtual Conference, and the Cowen 43rd Annual Health Care Conference. Nkarta is notably focused on developing engineered natural killer (NK) cell therapies aimed at treating cancer, utilizing cutting-edge technologies such as CRISPR.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nkarta is participating in multiple investor conferences, indicating interest and engagement.
  • The company is advancing its NK cell therapies, showcasing innovation in cancer treatment.
  • Nkarta's use of advanced technologies like CRISPR suggests robust development capabilities.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:
SVB Securities Global Biopharma Conference
3:40 p.m. ET – fireside chat
H.C. Wainwright Cell Therapy Virtual Conference
Time tbd – fireside chat
Cowen 43rd Annual Health Care Conference
2:10 p.m. ET – industry panel discussion
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:

Frequently Asked Questions

What is Nkarta, Inc. focused on?

Nkarta, Inc. specializes in engineered NK cell therapies for cancer treatment.

When will Nkarta participate in investor conferences?

Nkarta will participate in three investor conferences in February 2023.

Where can I watch Nkarta's conference webcasts?

Webcasts of the conferences will be available on Nkarta's Investors webpage.

What technologies does Nkarta utilize for its therapies?

Nkarta utilizes cell expansion, cryopreservation, and CRISPR-based engineering.

Tags: NKTX Viatris Investor Conferences Healthcare Nkarta investor conferences NK cell therapies biopharmaceuticals
Last updated: Feb 9, 2023